| Titre : | NEW COMORBIDITIES APPEARING AFTER ONE YEAR OF BIOLOGIC THERAPY IN PATIENTS WITH CIRD : PREVALENCE AND ASSOCIATED FACTORS | | Type de document : | thèse | | Auteurs : | TFARAH EL JOUMANI, Auteur | | Année de publication : | 2023 | | Langues : | Français (fre) | | Mots-clés : | comorbidities biologic therapy Rheumatoid Arthritis spondyloarthropathy. | | Résumé : | Objectives:
Determine the new comorbidities appearing under biologic therapy, their prevalence, and
associated factors.
Methods :
It’s a multicentric historical-prospective cohort including 10 rheumatology departments of
Moroccan University Hospitals. The data collected from the national registry of patients under
biologic therapy held by the Moroccan Society of Rheumatology. An electronic follow-up
questionnaire is completed every 6 months.
Results :
The study included 418 patients: 224 with Rheumatoid Arthritis (RA): 53.6% and 194 with
spondyloarthropathy (SP): 46.4%.
The prevalence rate of comorbidities appearing after one year of biologic therapy was 15.7% in
RA and 8.4% in SP. The rate of cardiovascular diseases was 12.9%. 6.4% was the same rate for
both hypercholesterolemia and depression, diabetes was 3.3%, gastric ulcer 3.2%, and
osteoporosis 9.7%. The sedentariness rate was 54.8%.
In the RA group, patients who developed a new comorbidity had a mean age of 51,8±11,3 years
old, women represented 87.5%, the average of Body Mass Index (BMI) was 27,6±5,9 and the
average duration of the disease was 14,1±9,2 years. The average disease activity score (DAS28)
was 3,15±1,47.
59.6% of patients used Rituximab, 23.8% Tociluzimab, 8.1% Etanercept, 5.8% Adalimumab,
0.2% Infliximab, and 0.9% Golimumab.
In the SP group, patients who developed a new comorbidity had a mean age of 40,2 ± 13,7 years
old, men represented 63.4%, and the average of BMI was 24,3 ± 4,94.
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 2,62 ± 1,79 and
Ankylosing Spondylitis Disease Activity Score (ASDAS) was 1,93 ± 1,09.
Regarding the type of biologic therapy, 33.2% of patients used Etanercept, 30.1% Adalimumab,
24.9% Infliximab, 9.8% Golimumab, 1.6% Secukinumab, and 0.5% Tociluzimab.
Conclusion :
Our study showed a high prevalence of cardiovascular disease in patients under biologic therapy.
This can be explained by the sedentary lifestyle.
Key words: comorbidities, biologic therapy, Rheumatoid Arthritis, spondyloarthropathy. | | Numéro (Thèse ou Mémoire) : | MS2042023 | | Directeur : | TAHIRI Latifa |
NEW COMORBIDITIES APPEARING AFTER ONE YEAR OF BIOLOGIC THERAPY IN PATIENTS WITH CIRD : PREVALENCE AND ASSOCIATED FACTORS [thèse] / TFARAH EL JOUMANI, Auteur . - 2023. Langues : Français ( fre) | Mots-clés : | comorbidities biologic therapy Rheumatoid Arthritis spondyloarthropathy. | | Résumé : | Objectives:
Determine the new comorbidities appearing under biologic therapy, their prevalence, and
associated factors.
Methods :
It’s a multicentric historical-prospective cohort including 10 rheumatology departments of
Moroccan University Hospitals. The data collected from the national registry of patients under
biologic therapy held by the Moroccan Society of Rheumatology. An electronic follow-up
questionnaire is completed every 6 months.
Results :
The study included 418 patients: 224 with Rheumatoid Arthritis (RA): 53.6% and 194 with
spondyloarthropathy (SP): 46.4%.
The prevalence rate of comorbidities appearing after one year of biologic therapy was 15.7% in
RA and 8.4% in SP. The rate of cardiovascular diseases was 12.9%. 6.4% was the same rate for
both hypercholesterolemia and depression, diabetes was 3.3%, gastric ulcer 3.2%, and
osteoporosis 9.7%. The sedentariness rate was 54.8%.
In the RA group, patients who developed a new comorbidity had a mean age of 51,8±11,3 years
old, women represented 87.5%, the average of Body Mass Index (BMI) was 27,6±5,9 and the
average duration of the disease was 14,1±9,2 years. The average disease activity score (DAS28)
was 3,15±1,47.
59.6% of patients used Rituximab, 23.8% Tociluzimab, 8.1% Etanercept, 5.8% Adalimumab,
0.2% Infliximab, and 0.9% Golimumab.
In the SP group, patients who developed a new comorbidity had a mean age of 40,2 ± 13,7 years
old, men represented 63.4%, and the average of BMI was 24,3 ± 4,94.
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 2,62 ± 1,79 and
Ankylosing Spondylitis Disease Activity Score (ASDAS) was 1,93 ± 1,09.
Regarding the type of biologic therapy, 33.2% of patients used Etanercept, 30.1% Adalimumab,
24.9% Infliximab, 9.8% Golimumab, 1.6% Secukinumab, and 0.5% Tociluzimab.
Conclusion :
Our study showed a high prevalence of cardiovascular disease in patients under biologic therapy.
This can be explained by the sedentary lifestyle.
Key words: comorbidities, biologic therapy, Rheumatoid Arthritis, spondyloarthropathy. | | Numéro (Thèse ou Mémoire) : | MS2042023 | | Directeur : | TAHIRI Latifa |
|
Accueil
Affiner la recherche Faire une suggestionLES COMORBIDITES DE LA BRONCHOPNEUMOPATHIE CHRONIQUE OBSTRUCTIVE / FNINE AZIZA
